An open-label, multicenter study to evaluate the DOSE, efficacy, safety and tolerability of PDNO (Nitrosooxypropanol) infusion in patients with pulmonary hypertension after cardiopulmonary bypass (CPB) surgery for Coronary artery bypass grafting (CABG) or mitral or Aortic valve repair or replacement with or without CABG
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Nitrosooxypropanol (Primary)
- Indications Postoperative hypertension; Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors Attgeno
Most Recent Events
- 31 Jul 2023 Planned End Date changed from 16 Nov 2022 to 31 Dec 2023.
- 31 Jul 2023 Planned primary completion date changed from 23 Apr 2023 to 31 Dec 2023.
- 17 Jan 2023 Status changed from not yet recruiting to recruiting.